PVRI 2023/24 Digital: Breaking barriers in pulmonary hypertension

Next session:

8 May 2024

  • days
  • Hours
  • Minutes

PVRI 2023/24 Digital is a monthly webinar series of cutting edge science

We are delighted to introduce our new webinar series, PVRI 2023/24 Digital, launching November 2023. The series follows the success of our PVRI 2021/22 series and has been developed by Dr Patricia Thistlethwaite MD, PhD, University of California San Diego.

 

The monthly webinars will take place on the second Wednesday of each month at 15:00 BST/GMT and will feature keynote talks from senior experts in the field as well as young investigators. In addition to our in-person meetings and symposia, this series will enable us to connect with our worldwide community, but also allow us to continue to explore and discuss important new research. During the live sessions, there will be ample time set aside for Q&A to encourage active participation from our audience. 

Scientific programme

Chromosome dynamics in pulmonary hypertension: mechanism and new treatments

8 May 2024, 3PM BST

Presentations:

  • Chromatin remodelling and enhancer distance in pulmonary arterial hypertension Kurt Stenmark 
  • Teleomere modulation in pulmonary hypertension 
  • Intergenic DNA mutations drive the development of pulmonary arterial hypertension
  • Chromosomal aberrations in pulmonary arterial hypertension Micheala Aldred 

Are mitochondria the instigator of pulmonary arterial hypertension?

12 June 3PM BST

Presentations:

  • Cell-to-cell transport of mitochondria as the cause of pulmonary vascular disease
  • Mitochondrial transplantation as treatment for pulmonary arterial hypertension
  • SNPs for sirtuin3 and uncoupling protein2 are causal of pulmonary arterial hypertension and diabetes disease severity
  • Therapeutic efficacy and mechanisms of Drpitor1a in pulmonary arterial hypertension.
  • Heteroplasmy of wild-type mitochondrial DNA variants causes metabolic heart disease with pulmonary hypertension

Autoimmune mechanisms in pulmonary arterial hypertension

10 July 2024, 3PM BST

Presentations:

  • Autoantibodies as the cause of pulmonary arterial hypertension Mark Toshner  
  • Pulmonary hypertension in myelodysplastic syndrome 
  • Prevalence and effect of myelofibrosis on pulmonary arterial hypertension 
  • Mast cells as the cause of pulmonary vascular remodeling in pulmonary arterial hypertension 
  • B-cell depletion with rituximab for the treatment of systemic sclerosis-associated pulmonary hypertension Roham Zamanian
  • Emergency myelopoiesis contributes to immune cell exhaustion in pulmonary vascular remodeling 

More webinars to be announced soon!

Our research platform is the world.

Through worldwide collaboration, we can begin to answer the question of a global disease.

Join the PVRI
standard-example-image.jpg